Figure 1
Double-purified LPS is a specific TLR4 agonist. (A) Effect of LPS (1 μg/mL), PepG (10 μg/mL), and Pam3Cys (10 μg/mL) on surface expression of CD25 in CD14/TLR4-transfected CHO cells (relative flow cytometry units are shown). The results of 1 representative experiment of 3 are presented. (B) Mean ( ± SEM) TNF-α levels in supernatants from LPS (10 ng/mL)–stimulated PBMCs in the absence or absence of the TLR4 antagonist B quintana (100 ng/mL) indicated by aTLR4 (N = 5, P < .01, compared with LPS stimulation). (C) Effect of LPS (1 μg/mL), PepG (10 μg/mL), and Pam3Cys (10 μg/mL) on surface expression of CD25 in CD14/TLR2-transfected CHO cells (relative flow cytometry units are shown). The results of 1 representative experiment of 3 are presented. (D) Mean (± SEM) TNF-α levels in 24-hour supernatants of LPS-stimulated PBMCs from 5 volunteers bearing wild-type NOD2 allele (NOD2 WT) and 4 persons with a frame-shift mutation in NOD2 (NOD2fs).

Double-purified LPS is a specific TLR4 agonist. (A) Effect of LPS (1 μg/mL), PepG (10 μg/mL), and Pam3Cys (10 μg/mL) on surface expression of CD25 in CD14/TLR4-transfected CHO cells (relative flow cytometry units are shown). The results of 1 representative experiment of 3 are presented. (B) Mean ( ± SEM) TNF-α levels in supernatants from LPS (10 ng/mL)–stimulated PBMCs in the absence or absence of the TLR4 antagonist B quintana (100 ng/mL) indicated by aTLR4 (N = 5, P < .01, compared with LPS stimulation). (C) Effect of LPS (1 μg/mL), PepG (10 μg/mL), and Pam3Cys (10 μg/mL) on surface expression of CD25 in CD14/TLR2-transfected CHO cells (relative flow cytometry units are shown). The results of 1 representative experiment of 3 are presented. (D) Mean (± SEM) TNF-α levels in 24-hour supernatants of LPS-stimulated PBMCs from 5 volunteers bearing wild-type NOD2 allele (NOD2 WT) and 4 persons with a frame-shift mutation in NOD2 (NOD2fs).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal